This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug MT
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor CI
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees MT
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen MT
Former Takeda Employee Pleads Guilty to Defrauding Company DJ
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema MT
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India MT
Transcript : Takeda Pharmaceutical Company Limited - Special Call
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints MT
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial MT
Takeda Pharmaceutical Company Limited to Present Positive Results from its Phase 2B Trial of TAK-861 CI
GSK blood cancer drug nearly halves risk of death in late-stage trial RE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma CI
Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM MT
Takeda Gets CHMP Approval for Recombinant ADAMTS13 DJ
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura CI
BHP pursuit of Anglo American highlights corporate-led UK M&A upswing RE
Evotec exits gene therapy business - slump in earnings at the start of the year RE
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment MT
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification MT
FDA extends review of Ascendis Pharma's hormone disorder therapy RE
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
Chart Takeda Pharmaceutical Company Limited
More charts
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,142 JPY
Average target price
4,768 JPY
Spread / Average Target
+15.11%
Consensus
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued